Healthcare, energy, industrials/materials, staples & telecom

Claim

Round 1 of the July "bee sweep" — the fields with no prior coverage. Five names survived the screen: ZTS (7.5), PPG (7.0), VZ (7.0), STZ (7.0), MPLX (7.0).

The screen's own meta-finding

"The rotation bought the label, not the cash flow."

Capital fleeing tech in 2026 bought defensiveness as a category. It did not discriminate on cash-flow quality within the category, so the label re-rated while the underlying economics did not. The same indiscriminacy that created the software opportunity in Act I ([[regime]]) operated here in reverse — and the same lesson applies: a sector-level flow is not a company-level thesis.

⛔ Rejected by the user, and why it matters

The user rejected all five on business-model grounds — explicitly ZTS, VZ and PPG — not on price. Direction changed to tech/software/hardware/emerging technology.

This is a preference constraint, not a valuation one, and it doesn't expire when prices move. Re-screening this field and re-surfacing these names would repeat work the user has already declined. Note this before running any defensive or dividend screen.

Earlier passes over the same ground: March 19 (BMY, GIS, ALL, MDT, UNH, STZ) and March 28 (healthcare, consumer, industrials, financials, energy, REITs). This field has now been swept three times.

⚠️ Amendment 2026-08-05 — the ZTS conviction of 7.5 is superseded

The sweep's ZTS score of [7.5] is superseded by [6.5] — Output/Stocks/Healthcare/ZTS/analyze-2026-08-05.md, the first full file on the name. The screen did not see the depth of the franchise problem: organic revenue growth is zero (the headline +3% is FX), US companion animal is −11%, Apoquel's core patent lapses ~2026 with generic oclacitinib arriving on top of Elanco's Zenrelia, and Elanco is attacking three franchises simultaneously. A screen-level conviction on a defensive name priced the label, not the competitive position — which is this note's own meta-finding, applied to one of its own outputs.

Two things worth keeping from the revision:

• The user's rejection was right, and for the right reason. They rejected ZTS on business model in July and independently re-stated the same worry on 2026-08-05 ("room to grow is genuinely low and getting narrower") before seeing any analysis. The rejection anticipated the finding. This raises the weight that should be given to the user's business-model objections generally — they are not a valuation preference in disguise.
• The rejection was directionally right but not a complete verdict. A steelman pass raised the score 6.0 → 6.5 and put ZTS on the watchlist rather than the discard pile: the cut guidance still implies +8.0% adjusted EPS growth, the contested dermatology franchise is $1.74B = 18.4% of revenue and grew 6% in FY2025, and ~70% of the business (livestock +12% organic, international companion animal +7% organic) is untouched. Correct on the business, incomplete on the price.

The constraint itself is unchanged and still live: do not re-surface these names from a screen. This analysis ran because the user re-opened ZTS directly, which supersedes the constraint for that name only.

What would falsify this

A genuine change in the user's mandate toward income. The framework already anticipates a growth→income transition, so this constraint is worth re-confirming rather than assuming permanent — but confirm with the user, don't infer it from a screen.

History

• 2026-03-19, 2026-03-28 — first two passes.
• 2026-07-29 — third pass; five survivors, all rejected by the user on business model.
• 2026-08-05 — ZTS [7.5] → [6.5], superseded by a full /analyze. User re-opened the name directly. Sweep-level conviction on a defensive name shown to have priced the label over the competitive position. See amendment above. AZN analysed the same day at [7.0] — a name this sweep never surfaced, and the better instrument for the same portfolio hole.